Child with Rare Disease Denied NRPD Aid – Centre Takes Matter to High Court
- Nishadil
- June 15, 2026
- 0 Comments
- 1 minutes read
- 17 Views
- Save
- Follow Topic
Government approaches High Court after child with rare disease is ruled ineligible for NRPD assistance
A young patient with a rare condition was turned down for help under the National Rare Diseases Programme, prompting the centre to seek clarification from the High Court.
When little Aarav was diagnosed with a rare metabolic disorder, his parents hoped the National Rare Diseases Programme (NRPD) would ease the financial strain. Instead, the application was rejected because his condition wasn’t on the official list of recognised ailments. It felt like a cruel twist of fate.
What followed was a flurry of media reports, petitions filed by the family and an outcry from several advocacy groups. The core of the controversy? The NRPD’s list—currently limited to about 165 diseases—leaves many genuine cases in limbo, and Aarav’s condition slipped through the cracks.
Facing growing pressure, the Centre decided to act. It has now approached the High Court, asking for a direction on whether the existing eligibility criteria can be broadened or at least interpreted more flexibly. The filing argues that denying aid on such technicalities contradicts the very spirit of the programme, which was meant to protect the most vulnerable.
The High Court is set to hear the matter next month. Lawyers for the Centre emphasize that a ruling in favour of a more inclusive approach could set a precedent, potentially opening doors for thousands of children whose rare diseases remain unlisted.
Meanwhile, Aarav’s family continues to grapple with daily challenges—medicines, hospital visits, and the constant worry that the system might not recognise their struggle. Their story has become a poignant reminder that policy, however well‑intentioned, must stay attuned to real‑world complexities.
Editorial note: Nishadil may use AI assistance for news drafting and formatting. Readers can report issues from this page, and material corrections are reviewed under our editorial standards.
